RPL34P19

Across TCGA pan-cancer cohorts, RPL34P19 RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated RPL34P19 data layer.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher RPL34P19 RNA is associated with better overall survival. In most high-consensus cancer types, elevated RPL34P19 expression acts as an unfavorable survival marker, although some lineages such as PAAD and SKCM show a favorable association.

PAAD, MESO, and BLCA are the cancer types where RPL34P19 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Tertile	All	0.758	0.430	<.001	102	view →
MESO	OS	Tertile	III,IV	0.394	0.573	.007	69	view →
BLCA	DFS	Tertile	II,III,IV	0.329	0.525	<.001	66	view →
CHOL	DFS	Tertile	III,IV	0.031	0.505	.003	54	view →
THCA	DFS	Tertile	All	0.448	0.867	<.001	45	view →
KIRC	DFS	Tertile	All	0.764	0.892	.002	45	view →
LIHC	OS	Tertile	II,III,IV	0.213	0.635	.012	36	view →
LUSC	OS	Tertile	IV	0.001	0.673	.014	36	view →
SKCM	DFS	Tertile	All	0.863	0.717	.001	30	view →
OV	OS	Tertile	III,IV	0.776	0.853	.018	12	view →
UCEC	DFS	Tertile	All	0.735	0.848	.020	12	view →
ACC	DFS	Tertile	IV	0.121	0.417	.039	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 15 lineages.

RPL34P19–PAAD (OS)

Open the PAAD breakdown →